Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

The Business of Branding: Websites Aren't Built in a Day

Jeffrey Morgan

In the first two parts of this article, the author discussed the designing and building an effective website. In this final installment, he reviews the development phase and provides an overview of the entire process.

Features

13 Ways to Amplify Your Communications

Nicholas Gaffney & Ritchenya Dodd

Here are 13 tips to amplify your communications programs to meet the challenges of 2013 and beyond.

Disclosure of ADR Affiliation

Scott Graham

California's Second District Court of Appeal recently established a bright-line rule when it held that a lawyer's membership in the ADR provider deciding his case must be disclosed to the other side.

The Duty to Notify an Excess Carrier: Considerations for Defense Counsel

Michael D. Brophy

The relationship between a primary and excess insurance carrier within the context of a catastrophic medical malpractice litigation is fraught with possible pitfalls.

Columns & Departments

Business Crimes Hotline

ALM Staff & Law Journal Newsletters

A look at a recent case in which the DOJ leveraged FIRREA.

In the Courts

ALM Staff & Law Journal Newsletters

In-depth analysis of a recent key ruling.

Defending Against Asset Forfeiture

Jonathan B. New & Christy Nixon

Given the DOJ's aggressive use of asset forfeitures, including higher-value forfeitures, counsel should be prepared to seek <i>Monsanto</i> hearings.

Features

Navigating Turbulent FCPA Waters

Joseph F. Savage, Jr. & Maren Klawiter

While there have been high-profile setbacks to be sure, there is little reason to expect FCPA enforcement actions ' characterized by some as a tool in the war on terror ' to decline.

Features

Key Elements of Effective FCPA Remediation: Earning DOJ and SEC's 'High Premium'

Jonny Frank & Rex Homme

The Department of Justice (DOJ) and Securities Exchange Commission's (SEC) Guide to the U.S. Foreign Corrupt Practices Act (FCPA) demonstrates, if there were any doubt, the importance of timely and effective FCPA remediation.

Adverse Event Reporting for Pharmaceutical Products

Alan Minsk

The Food and Drug Administration (FDA) provides some protection to drug companies regarding adverse event reports by allowing a disclaimer statement about liability. However, this is not a blanket defense against other potential liability exposure.

Need Help?

  1. Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
  2. Need other assistance? email Customer Service or call 1-877-256-2472.

MOST POPULAR STORIES